Spermosens is organizing a Q&A session for shareholders and stakeholders to interact directly with the CEO following the release of their Q1 2026 report. This session is part of their regular investor engagement efforts, typically held a week after quarterly report releases. The webcast is scheduled for May 19, 2026, at 12:00 CET, and will be conducted in English and Swedish. Participants can submit questions in advance by emailing Spermosens, with a submission deadline of May 18, 2026. Spermosens AB, based in Sweden, is a biotechnology company focused on improving fertility treatments through innovative diagnostics. Their JUNO-Checked product enhances fertility diagnostics precision. The company's shares are listed on the Spotlight Stock Market under the code SE0015346424.

The Capital Facility provides Spermosens with financial flexibility to continue its commercial plan and complete the clinical validation of its product, JUNO-Checked Generation 3. It includes a warrant component incentivizing investors and aligning their interests with the company's long-term share price development. The Board of Directors sees this facility as a cost-efficient solution in the current financing environment. CEO Tore Duvold highlights that the facility allows the company to focus on commercialization without distraction. Investors, including Mount Nebo Capital, have committed SEK 4.85 million, which can be accessed between June and December 2026. The drawdown will be through a directed issue of units, each comprising one share and one warrant. The subscription price is set at a 15% discount to the average share price following a capital call. The facility requires approval from the annual general meeting in June 2026, with specific resolutions for the directed issue needing extraordinary general meeting approval. Spermosens, a Swedish biotechnology company, focuses on advancing fertility diagnostics and is listed on the Spotlight Stock Market.

During the first quarter of 2026, Spermosens made significant advancements in male fertility diagnostics. They signed Memorandums of Understanding with Sapyen and RSI to enhance diagnostic capabilities, particularly in the US. They completed the development of their JUNO-Checked Generation 3 system and began a clinical validation study in April. Financially, the company reported no net sales and an operating loss of SEK 2,175,000 for Q1 2026, with cash and cash equivalents at SEK 4,481,000. The CEO highlighted their strategic focus on technology development, clinical validation, and commercial partnerships, emphasizing the importance of functional testing and partner-driven commercialization. The company aims to formalize agreements and has a financial strategy to bridge capital needs until revenue from license agreements materializes. A live Q&A webcast with shareholders was held, underscoring the importance of shareholder engagement.

Spermosens AB has completed the development of its Generation 3 system and has started a clinical validation study at the RMC in Malmö. The study focuses on couples undergoing IVF treatment due to unexplained infertility, where standard sperm analysis shows normal results. The JUNO-Checked system measures the sperm's ability to bind to the egg, which is crucial for fertilization. The aim is to identify causes of fertilization failure not detected by standard tests. The study is progressing as planned, with completion expected by the end of 2026. Spermosens intends to commercialize JUNO-Checked globally through licensing or partnerships. CEO Tore Duvold reports that the study is on schedule, with successful initial testing of seven patients. Spermosens is a Swedish biotechnology company specializing in fertility diagnostics, with its shares listed on the Spotlight Stock Market.

The JUNO-Checked Generation 3 system, developed by Spermosens AB, has been enhanced to meet the needs of clinics and laboratories with improved analysis times and a robust sensor design. These upgrades aim to reduce risks and facilitate integration into existing lab environments. A clinical validation study will be conducted at the Reproductive Medicine Center in Malmö, focusing on IVF cases with unexplained infertility to demonstrate additional diagnostic value. The study is expected to complete by year-end, with successful validation paving the way for market introduction through licensing or co-development. Spermosens targets the global fertility market, aiming to improve diagnostic precision and treatment outcomes. CEO Dr. Tore Duvold expressed satisfaction with the progress and emphasized the importance of the upcoming validation study. Spermosens AB is a Swedish biotechnology company dedicated to advancing fertility diagnostics, with its shares listed on the Spotlight Stock Market.

The session is a platform for CEO Tore Duvold to discuss the company's recent technical achievements, clinical evidence, and move towards commercial partnerships. The focus is on replacing estimation with evidence in the global fertility diagnostics market as they finalize Generation 3.0 and implement a partner-led strategy. The webcast is scheduled for Thursday, 26 March 2026, at 12:00 CET, in English and Swedish. Participants are encouraged to submit questions by 25 March 2026. Spermosens, a Swedish biotechnology company, specializes in fertility diagnostics, aiming to improve outcomes through innovative technologies like their product JUNO-Checked, which enhances precision in fertility evaluations. The company collaborates with research institutions and is listed on the Spotlight Stock Market as SPERM.

The session is a Q&A organized to allow shareholders and stakeholders to engage with the Company following the clinical validation of the JUNO-Checked system and its move towards commercial partnerships. This webcast aims to discuss the Company's position in the global fertility diagnostics market. Spermosens plans to make these Q&A sessions a regular event, usually held about a week after each quarterly report. The webcast is scheduled for Thursday, 26 March 2026, at 12:00 CET in English and Swedish, accessible via a provided link. Participants can submit questions in advance by emailing info@spermosens.com, with a deadline of 25 March 2026. Spermosens AB, a Swedish biotechnology company, focuses on fertility diagnostics, developing technologies to improve fertility outcomes. Their product, JUNO-Checked, enhances diagnostic precision by measuring sperm-egg binding capacity, aiding clinical decisions and treatment strategies. The company collaborates with research institutions and is listed on the Spotlight Stock Market as SPERM. More information can be found on their website.

The year-end report for Spermosens was initially omitted from a press release but is now available. Spermosens has achieved significant progress by focusing on evidence-based development of their diagnostic tool for male fertility, which addresses a major gap in reproductive healthcare. In 2025, they received patent approvals in several countries and made strides in partner-driven commercialization. Financially, the company reported no net sales, with an operating loss slightly improved from the previous year. They have a strong equity/assets ratio and liquidity ratio, with a notable increase in cash and cash equivalents. Significant events include patent approvals and partnerships to advance male fertility diagnostics. CEO Tore Duvold highlighted the company's unique technology and patent portfolio, emphasizing their progress in turning inventions into market-ready products. Their clinical study showed promising results for their JUNO-Checked diagnostic tool, which measures sperm's ability to bind to the egg. The company expanded its intellectual property and is working towards commercialization with partners in key markets. They secured strategic investments and are developing their Generation 3 system, aiming for completion in the first half of 2026. The focus remains on clinical validation and integration into fertility workflows, with the goal of creating long-term value for shareholders by addressing infertility challenges.

Spermosens has focused on transforming its invention into a viable product by emphasizing evidence-based development. In 2025, the company received patent approvals in several countries, including Canada, Mexico, Israel, and China. They also announced the outcome of warrant exercises and plans for commercialization. After the interim period, Spermosens signed Memoranda of Understanding with Sapyen and RSI to advance male fertility diagnostics. Financially, Spermosens reported no net sales for 2025, with an operating loss of SEK 9,201 thousand. Cash and cash equivalents increased significantly, and the equity/assets ratio improved to 95%. The company had four employees by the end of the period. CEO Tore Duvold highlighted the completion of a clinical study demonstrating the effectiveness of their diagnostic tool, JUNO-Checked, in addressing male infertility. The company expanded its intellectual property and is working towards commercialization with strategic partnerships. A strategic investment was secured in early 2025, supporting their mission to integrate technology into modern fertility practices. The development of their Generation 3 system is on track, aimed at improving throughput and ease of use, with completion expected in the first half of 2026. The focus remains on validating this system and advancing partnerships for commercialization.

Male fertility diagnostics face challenges related to sample quality and standardization. RSI has developed devices like the ProteX™ collection system and NovoSort® sperm processing technology to improve sperm quality and laboratory workflows. Spermosens and RSI have signed a non-binding Memorandum of Understanding (MoU) to evaluate how Spermosens' JUNO‑Checked can be integrated with RSI's devices to provide better clinical insights into male fertility. The MoU aims to assess technical compatibility, feasibility, and regulatory considerations in the US fertility care market. Spermosens seeks to introduce JUNO-Checked to clinics worldwide through partnerships. Tore Duvold, CEO of Spermosens, highlights the potential of JUNO‑Checked to enhance fertility diagnostics, while Sam Marple, CEO of RSI, notes the alignment of their technologies with clinical needs. Spermosens is a Swedish biotechnology company focused on fertility diagnostics, and RSI is a US-based medical device company specializing in sperm collection and preparation solutions.